China: Value-Based Procurement Reshapes Strategies Of Multinational Medtech Firms

China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.  

Map of China in magnifying glass (shutterstock)
• Source: Shutterstock

Regarding the key players, with a valuation more than triple that of the following competitor, Mindray Medical is the clear market leader in the medical device market with market value of CNY326bn ($44.8bn) in 2020. Next performers are Wantai Biological (CNY86bn), Lepu Medical (CNY79bn), BGI Group (CNY75bn), New Industries (CNY75bn), Autobio Diagnostics (CNY69bn) and Jafron Biomedical (CNY59bn).

In some areas, domestic companies are markedly improving their performance across operations. China’s 134 listed medtech companies generated $44bn in...

More from Global Vision

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.